DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rv6z48/_human) has announced the addition of the "Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.
The global HPV therapeutics market was valued at USD 1,402.3 million in 2012 and is expected to reach USD 2,346.5 million by 2020, growing at a CAGR of 7.7% from 2014 to 2020.
Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins.
The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections.
The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others).
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Global HPV and CMV Therapeutics Market Overview
Chapter 4 Global HPV Therapeutics Market
Chapter 5 Global Cytomegalovirus Therapeutics Market
Chapter 6 Global HPV and CMV Therapeutics Market, by Geography
Chapter 7 Recommendations
Chapter 8 Company Profiles
- AbbVie, Inc.
- Actavis plc
- Clinigen Group plc
- Merck & Co., Inc.
- Perrigo Company plc
- Roche Holdings AG
- Valeant Pharmaceuticals International, Inc.
For more information visit http://www.researchandmarkets.com/research/rv6z48/_human